TY - JOUR
T1 - Fibrosis and secondary lymphedema
T2 - chicken or egg?
AU - Kataru, Raghu P.
AU - Wiser, Itay
AU - Baik, Jung Eun
AU - Park, Hyeung Ju
AU - Rehal, Sonia
AU - Shin, Jin Yeon
AU - Mehrara, Babak J.
N1 - Publisher Copyright:
© 2019 Elsevier Inc.
PY - 2019/7
Y1 - 2019/7
N2 - Secondary lymphedema is a common complication of cancer treatment resulting in progressive fibroadipose tissue deposition, increased risk of infections, and, in rare cases, secondary malignancies. Until recently, the pathophysiology of secondary lymphedema was thought to be related to impaired collateral lymphatic formation after surgical injury. However, more recent studies have shown that chronic inflammation-induced fibrosis plays a key role in the pathophysiology of this disease. In this review, we will discuss the evidence supporting this hypothesis and summarize recent publications demonstrating that lymphatic injury activates chronic immune responses that promote fibrosis and lymphatic leakiness, decrease collecting lymphatic pumping, and impair collateral lymphatic formation. We will review how chronic mixed T-helper cell inflammatory reactions regulate this process and how this response may be used to design novel therapies for lymphedema.
AB - Secondary lymphedema is a common complication of cancer treatment resulting in progressive fibroadipose tissue deposition, increased risk of infections, and, in rare cases, secondary malignancies. Until recently, the pathophysiology of secondary lymphedema was thought to be related to impaired collateral lymphatic formation after surgical injury. However, more recent studies have shown that chronic inflammation-induced fibrosis plays a key role in the pathophysiology of this disease. In this review, we will discuss the evidence supporting this hypothesis and summarize recent publications demonstrating that lymphatic injury activates chronic immune responses that promote fibrosis and lymphatic leakiness, decrease collecting lymphatic pumping, and impair collateral lymphatic formation. We will review how chronic mixed T-helper cell inflammatory reactions regulate this process and how this response may be used to design novel therapies for lymphedema.
UR - http://www.scopus.com/inward/record.url?scp=85065059210&partnerID=8YFLogxK
U2 - 10.1016/j.trsl.2019.04.001
DO - 10.1016/j.trsl.2019.04.001
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???
C2 - 31022376
AN - SCOPUS:85065059210
SN - 1931-5244
VL - 209
SP - 68
EP - 76
JO - Translational Research
JF - Translational Research
ER -